Collegium Pharmaceutical (COLL)
NASDAQ:COLL
COLL Stock Chart & Stats
$35.47
$3.70(12.70%)
At close: 4:00 PM EST
$35.47
$3.70(12.70%)
Day’s Range― - ―
52-Week Range$25.87 - $50.79
Previous CloseN/A
Volume233.62K
Average Volume (3M)600.75K
Market Cap
$1.13B
Enterprise Value$1.82B
Total Cash (Recent Filing)$406.53M
Total Debt (Recent Filing)$940.56M
Price to Earnings (P/E)21.6
Beta0.49
Next Earnings
May 07, 2026EPS Estimate
1.79Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)2.04
Shares Outstanding31,753,210
10 Day Avg. Volume496,834
30 Day Avg. Volume600,753
Financial Highlights & Ratios
PEG Ratio-3.12
Price to Book (P/B)4.87
Price to Sales (P/S)1.88
P/FCF Ratio4.48
Enterprise Value/Market Cap1.61
Enterprise Value/Revenue2.33
Enterprise Value/Gross Profit3.92
Enterprise Value/Ebitda3.03
Forecast
1Y Price Target
$54.17Price Target Upside52.72% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)8.05
Revenue Forecast (FY)$809.89M
Bulls Say, Bears Say
Bulls Say
ADHD Franchise ExpansionAcquisition of AZSTARYS broadens the ADHD product lineup with a complementary branded option, enhancing long-term revenue visibility and enabling share gains versus generic alternatives.
Commercial Synergies And Margin ImprovementAnalyst projects that integrating AZSTARYS into the existing ADHD commercial infrastructure will generate sales synergies and operational efficiencies that improve margins and raise adjusted EBITDA.
Jornay Growth And Cash GenerationStrong performance of the Jornay sleep product underpins durable cash flows and healthy operating cash conversion, supporting capital deployment for further value-accretive initiatives.
Bears Say
Authorized Generics PressureLaunches of authorized generics for Nucynta immediate-release and extended-release increase competitive pressure on the pain franchise and may erode revenue and margin contribution from those products.
Elevated Acquisition ValuationAnalyst warns the deal valuation appears elevated, which could strain returns if the new asset does not fully offset revenue declines from other products losing exclusivity.
Reliance On Business DevelopmentRising pressure on the pain portfolio heightens dependence on successful business development to add a replacement commercial product, leaving growth vulnerable if deals are delayed or underperform.
Collegium Pharmaceutical News
COLL FAQ
What was Collegium Pharmaceutical’s price range in the past 12 months?
Collegium Pharmaceutical lowest stock price was $25.86 and its highest was $50.79 in the past 12 months.
What is Collegium Pharmaceutical’s market cap?
Collegium Pharmaceutical’s market cap is $1.13B.
When is Collegium Pharmaceutical’s upcoming earnings report date?
Collegium Pharmaceutical’s upcoming earnings report date is May 07, 2026 which is in 24 days.
How were Collegium Pharmaceutical’s earnings last quarter?
Collegium Pharmaceutical released its earnings results on Feb 26, 2026. The company reported $2.04 earnings per share for the quarter, missing the consensus estimate of $2.139 by -$0.099.
Is Collegium Pharmaceutical overvalued?
According to Wall Street analysts Collegium Pharmaceutical’s price is currently Undervalued.
Does Collegium Pharmaceutical pay dividends?
Collegium Pharmaceutical does not currently pay dividends.
What is Collegium Pharmaceutical’s EPS estimate?
Collegium Pharmaceutical’s EPS estimate is 1.79.
How many shares outstanding does Collegium Pharmaceutical have?
Collegium Pharmaceutical has 31,753,210 shares outstanding.
What happened to Collegium Pharmaceutical’s price movement after its last earnings report?
Collegium Pharmaceutical reported an EPS of $2.04 in its last earnings report, missing expectations of $2.139. Following the earnings report the stock price went down -3.344%.
Which hedge fund is a major shareholder of Collegium Pharmaceutical?
Currently, no hedge funds are holding shares in COLL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Collegium Pharmaceutical Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$54.17 (52.72% Upside)
$54.17 (52.72% Upside)
Blogger Sentiment
Bullish
COLL Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 48.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.9%
Last 30 Days ▼ 6.1%
Last 30 Days ▼ 6.1%
Technicals
SMA
Negative
20 days / 200 days
Momentum
43.77%
12-Months-Change
Fundamentals
Return on Equity
24.11%
Trailing 12-Months
Asset Growth
1.35%
Trailing 12-Months
Company Description
Collegium Pharmaceutical
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol; and Xtampza ER for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.
COLL Company Deck
COLL Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call emphasizes strong, broad-based commercial performance (notably Jornay PM) and robust financial outcomes for 2025 — record revenue, record adjusted EBITDA, strong cash generation, and materially improved leverage. Management reiterated disciplined capital deployment, added liquidity via a $980M syndicated facility, and expects Jornay to be a key growth driver in 2026 (guiding Jarday revenue +~31% YoY). However, near-term headwinds and risks include substantial increases in operating expenses due to commercialization investments, elevated gross-to-net rates (≈64%), expected seasonal Q1 pressure, a Q4 decline in Xtampza, and the impact of an authorized generic for Nucynta (partially mitigated by profit share). Overall, the positives (revenue growth, cash flow, leverage improvement, Jornay momentum, strategic financing) materially outweigh the lowlights, which are largely investment- and seasonality-driven.View all COLL earnings summariesCOLL Stock 12 Month Forecast
Average Price Target
$54.17
▲(52.72% Upside)
Technical Analysis
―
Pacira Pharmaceuticals
―
Supernus Pharmaceuticals
―
ANI Pharmaceuticals
―
Amphastar Pharmaceuticals
―
Ownership Overview
Currently, No data available
---